Is Novartis India a good stock to invest in?

Novartis India can be analyzed on the following key metrics - TTM P/E: 19.21 Sector P/E: 22.67 Dividend Yield: 2.47% D/E ratio: -

Novartis India Share Price

Sector: Biotechnology & Drugs

Powered by

1002.90 -7.95 (-0.79%)

1D
5D
1M
3M
6M
1Y
5Y
MAX

Price Range

Today’s Low 996.95

Today’s High 1019.90

52 Week Low 744.95

52 Week High 1248.00

Key Metrics

Market Cap (In Cr) 2476.24
Beta 0.48
Div. Yield (%) 2.47
P/B 3.18
TTM P/E 19.21
Peg Ratio 0.56
Sector P/E 22.67
D/E 0
Open Price 1019.9
Prev Close 1010.85

View All Metrics

Novartis India Analysis

Price Analysis

1 Week

1.19%
3 Months

25.24%
6 Month

7.3%
YTD

9.9%
1 Year

-8.12%

Risk Meter

31% Low risk
31% Moderate risk
31% Balanced Risk
31% High risk
31% Extreme risk

Novartis India News

Cardiovascular diseases account for a quarter of all deaths in India.

Premium

Genetics can spike Indians' cholesterol, but relief may be at hand

6 min read . 14 Apr 2025

Sundar Pichai, CEO of Alphabet, is one of the most popular Indian-origin chiefs in the corporate world. (REUTERS)

Premium

From Alphabet to Adobe and Chanel: Check 20 top global CEOs of Indian origin

4 min read . 28 Nov 2024

Premium

Novartis India Q2 Results Live: Profit Falls by 13.81% YOY

1 min read . 27 Oct 2024

Companies reporting results on Tuesday, 30 July include Tata Consumer Products, Indian Oil Corporation, Exide Industries, GAIL, Titagarh Rail Systems, Indus Towers, Jindal Stainless, Dixon Tech, Granules India, Macrotech Developers, Castrol India, Shyam Metalics, Star Insurance, RR Kabel, Sapphire Foods, Lloyds Metals & Energy, Torrent Power, TVS Supply Chain Solutions, and Varun Beverages, among others. (Photo: AP)

Premium

Stocks to watch: HPCL, Colgate, Pfizer, ACC, Kansai Nerolac, BEL, Arvind

8 min read . 30 Jul 2024

View More News

Novartis India Financials

INCOME
BALANCE SHEET
Cashflow

DATE

Annual

Quarterly

Period
2025

Total Revenue
356.27

Selling/ General/ Admin Expenses Total
18.55

Depreciation/ Amortization
2.19

Other Operating Expenses Total
43.48

Total Operating Expense
267.04

Operating Income
89.23

Net Income Before Taxes
130.42

Net Income
100.9

Diluted Normalized EPS
40.87

Period
2024

Total Revenue
335.07

Selling/ General/ Admin Expenses Total
60.65

Depreciation/ Amortization
2.61

Other Operating Expenses Total
6.51

Total Operating Expense
272.15

Operating Income
62.92

Net Income Before Taxes
122.84

Net Income
85.19

Diluted Normalized EPS
32.85

Period
2023

Total Revenue
378.74

Selling/ General/ Admin Expenses Total
97.05

Depreciation/ Amortization
6.06

Other Operating Expenses Total
10.93

Total Operating Expense
318.66

Operating Income
60.08

Net Income Before Taxes
115.38

Net Income
103.36

Diluted Normalized EPS
40.81

Period
2022

Total Revenue
399.87

Selling/ General/ Admin Expenses Total
188.65

Depreciation/ Amortization
9.65

Other Operating Expenses Total
2.5

Total Operating Expense
431.91

Operating Income
-32.04

Net Income Before Taxes
-3.82

Net Income
-3.72

Diluted Normalized EPS
11.6

Period
2021

Total Revenue
381.35

Selling/ General/ Admin Expenses Total
197.1

Depreciation/ Amortization
12.16

Other Operating Expenses Total
7.69

Total Operating Expense
366.58

Operating Income
14.77

Net Income Before Taxes
40.04

Net Income
20.9

Diluted Normalized EPS
7.5

Period
2020

Total Revenue
438.25

Selling/ General/ Admin Expenses Total
231

Depreciation/ Amortization
13.14

Other Operating Expenses Total
7.91

Total Operating Expense
437.41

Operating Income
0.84

Net Income Before Taxes
28.64

Net Income
10.08

Diluted Normalized EPS
6.52

View detailed financials

Forecast

Income Sheet (In Cr) Net Income Vs Revenue

Returns Metrics (In Cr) ROA Vs ROE

Forecast

Balance Sheet Asset vs Liability

Forecast

Cash Flow Operating vs Investing

Novartis India Technical

Moving Average SMA

5 Day1011.33
10 Day1007.87
20 Day1014.22

50 Day915.8
100 Day867.55
300 Day946.72

Novartis India Peers

Price
Ratio

Name
Latest Price
Change
% Change
52W High
52W Low
Mkt. Cap

Gujarat Themis Biosyn
349.5
3.85
1.11
390
192.35
3839.06

Panacea Biotec
413.15
4.25
1.04
581
129.65
2544.4

Novartis India
1002.9
-7.95
-0.79
1248
744.95
2476.24

Sms Pharmaceuticals
248.55
1.8
0.73
398
175
2199.77

Amrutanjan Health Care
735.35
7.5
1.03
861.4
548.05
2140.7

Novartis India Shareholding

Shareholding Pattern

Shareholding Trend

Shareholding(%) v/s Date

View All

Corporate Actions

Board Meeting
AGM
Dividends
Bonus
Split
Rights

Meeting Date
Purpose

09-May-25
Audited Results & Final Dividend

28-Jan-25
Quarterly Results

25-Oct-24
Quarterly Results

10-May-24
Audited Results & Final Dividend

25-Jan-24
Quarterly Results

27-Oct-23
Quarterly Results

26-Jul-23
Quarterly Results

10-May-23
Audited Results, Final & Special Dividend

08-Feb-23
Quarterly Results

09-Nov-22
Quarterly Results

Meeting Date
Announced on
Purpose

31-Jul-25
09-May-25
AGM

17-Jun-25
16-May-25
POM

31-Jul-24
10-May-24
AGM

23-Mar-24
20-Feb-24
POM

29-Jul-22
19-May-22
AGM

27-Aug-21
17-Jun-21
AGM

25-Mar-21
22-Feb-21
POM

-
10-May-23
AGM

Announced on
Record Date
Ex-Dividend
Dividend Value

09-May-25
23-Jul-25
23-Jul-25
25

10-May-24
-
23-Jul-24
25

10-May-23
-
20-Jul-23
10

11-May-23
-
20-Jul-23
37.5

19-May-22
-
20-Jul-22
10

17-Jun-21
-
17-Aug-21
10

View All

Company Profile

ABOUT Novartis India

Industry Biotechnology & Drugs
ISIN INE234A01025
BSE Code 500672
NSE Code NOVARTIND

Novartis India Limited is an India-based company. The Company is primarily engaged in the business of trading of Pharmaceuticals. It operates in the Pharmaceutical business segment. The Company’s brands hold key positions in therapeutic areas, such as, Voveran, which is the brand for bone and pain; Simulect, Certican, Sandimmun, Neoral, and Myfortic, which is the brand for transplantation immunology; and Tegrital and Exelon, which is the brand for neurosciences.

MANAGEMENT

Shilpa Joshi Chief Financial Officer, Whole-Time Director
Chandni Maru Chief Compliance Officer, Company Secretary
Falin Ishwarlal Majmudar Additional Director (Whole-Time Director)

NOVARTIS INDIA SUMMARY

Novartis India is trading 0.79% lower at Rs 1002.90 as compared to its last closing price. Novartis India has been trading in the price range of 1019.90 & 996.95. Novartis India has given 9.9% in this year & 1.19% in the last 5 days.

Novartis India has TTM P/E ratio 19.21 as compared to the sector P/E of 22.67.

The company posted a net profit of 29.3 Crores in its last quarter.

Listed peers of Novartis India include Gujarat Themis Biosyn (1.11%), Panacea Biotec (1.04%), Novartis India (-0.79%) etc.

Novartis India has a 70.68% promoter holding & 29.32% public holding.

FAQs about Novartis India

Novartis India is trading at 1002.90 as on 27 Jun, 2025 3:50:55 PM. This is -0.79% lower as compared to its previous closing price of 1010.85

The market capitalization of Novartis India is 2476.24 Cr as on 27 Jun, 2025 3:50:55 PM.

The 52 wk high for Novartis India is 1248.00 whereas the 52 wk low is 744.95

Novartis India can be analyzed on the following key metrics -

TTM P/E: 19.21
Sector P/E: 22.67
Dividend Yield: 2.47%
D/E ratio: -

Novartis India reported a net profit of 100.9 Cr in 2025.

Novartis India Quick Links

Equity Quick Links

Top Gainers | Top Losers | Indian Indices | BSE Active Stocks | NSE Active Stocks

Novartis India Share Price

Price Range

Key Metrics

Novartis India Analysis

Novartis India News

Genetics can spike Indians' cholesterol, but relief may be at hand

From Alphabet to Adobe and Chanel: Check 20 top global CEOs of Indian origin

Novartis India Q2 Results Live: Profit Falls by 13.81% YOY

Stocks to watch: HPCL, Colgate, Pfizer, ACC, Kansai Nerolac, BEL, Arvind

Novartis India Financials

Forecast

Forecast

Forecast

Novartis India Technical

Novartis India Peers

Novartis India Shareholding

Shareholding Pattern

Shareholding Trend

Corporate Actions

Company Profile

ABOUT Novartis India

MANAGEMENT

NOVARTIS INDIA SUMMARY

FAQs about Novartis India

Wait for it…

Wait for it…

Congratulations!

Subscribe to continue